Eurofins expands in India

Acquires biopharmaceutical company Advinus from Tata Group


Eurofins Scientific announces that it has signed an exclusive agreement with Tata Group to acquire Advinus Therapeutics, a preclinical and clinical phase contract research company for Safety Assessment, DMPK, CMC services, and Analytical R&D Services. The transaction is expected to close in the next few weeks, subject to the fulfilment of customary closing conditions.

With over 25 years of GLP compliance and certification, Advinus serves diverse industries such as Biotech, Pharmaceuticals, Biologics, Agrochemicals, Nutraceuticals and Cosmetics. Advinus has submitted over 50 end-to-end investigational new drug applications (INDs) to global regulators such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory Agency in the UK (MHRA) and Health Canada among others. Located in Bangalore, India, the company operates a state-of-the art 20,000 m2 facility on a large campus with ample space for expansion. The company generated revenues of EUR 17m in the Fiscal Year ending 31 March 2017 with over 300 staff.

Advinus’ expertise complements Eurofins recent contract research, development and manufacturing (CDMO) capabilities following the acquisitions of Alphora in Canada and Amatsigroup in Europe. The company provides GMP testing and manufacturing capabilities, and is well positioned to capitalize on the growing R&D outsourcing market in the Asia-Pacific region.

Comment from Mr. KRS Jamwal, Chairman of Advinus and Executive Director of Tata Industries: “Advinus has developed significant promise under Tata parenting, and will now realise its full potential joining the Eurofins family of laboratories. We are confident that with access to Eurofins’ global network and technical competencies, Advinus will be able to rapidly expand its analytical portfolio and services to benefit all its existing and future clients.”

Comment from Dr. Gilles Martin, Eurofins CEO: “We are pleased to welcome Advinus Therapeutics to the Eurofins Group. Advinus’ competencies and footprint further strengthen Eurofins’ global leadership in the rapidly-growing biopharmaceutical testing market. We are committed to supporting Advinus’ further development by providing access to the full range of services and capabilities of the Group to the company and its clients.”

Eurofins Scientific Services NV

Recommend news PDF version / Print

Share on

Facts, background information, dossiers
  • contract research o…
  • contract development
  • contract research
  • contract manufacturing
  • pharmaceutical cont…
  • Eurofins
  • Tata Group
  • divestments
  • acquisitions
More about Eurofins
  • News

    Eurofins expands its specialty diagnosis branch

    Eurofins Scientific announces the acquisition of NMDL-LCPL, a specialized medical testing business providing molecular diagnostics and pathology laboratory services. NMDL-LCPL is comprised of the Nederlands Moleculair Diagnostisch Laboratorium (“NMDL”) and the Leids Cytologisch Pathologisch ... more

    Eurofins expands in clinical diagnostics

    Eurofins Scientific announces the acquisition of Labo Van Poucke (“LVP”), a leading laboratory performing human medical testing covering all branches of clinical biology. LVP was founded in 1969 and has been a 100% family-owned business ever since. LVP performs almost all medical analyses c ... more

    Selcia joins Eurofins Group

    Selcia Limited announces that it has been acquired by Eurofins Scientific, a global leader in analytical testing and pharma discovery services. The acquisition of Selcia provides Eurofins with an entry into the custom radiolabelling and innovative pre-clinical, integrated drug discovery ser ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE